Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-22
DOI
10.1038/s41467-021-25379-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells
- (2020) Veronika Kozlova et al. PLoS One
- Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial
- (2020) Fabian Knörr et al. JOURNAL OF CLINICAL ONCOLOGY
- 1030P First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation
- (2020) I. Puzanov et al. ANNALS OF ONCOLOGY
- CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
- (2020) Francesca Zammarchi et al. Journal for ImmunoTherapy of Cancer
- Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial
- (2020) Lara Mussolin et al. Cancers
- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- Next-generation characterization of the Cancer Cell Line Encyclopedia
- (2019) Mahmoud Ghandi et al. NATURE
- The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma
- (2018) Nikolai Schleussner et al. LEUKEMIA
- Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
- (2018) Geeta Sharma et al. Cancers
- Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma
- (2018) Nicole Prutsch et al. LEUKEMIA
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
- (2018) Steven Horwitz et al. LANCET
- IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability
- (2018) T. Tiffany Wang et al. LEUKEMIA
- Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
- (2017) Fabian Knörr et al. HAEMATOLOGICA
- Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study
- (2017) Yael P. Mossé et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary cutaneous anaplastic large cell lymphoma
- (2017) Ryanne A. Brown et al. JOURNAL OF CUTANEOUS PATHOLOGY
- An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma
- (2017) A Lollies et al. LEUKEMIA
- Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations
- (2017) Jing Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
- (2017) Berkley E. Gryder et al. Cancer Discovery
- Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
- (2017) Fabian Knörr et al. HAEMATOLOGICA
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
- (2016) M. J. Flynn et al. MOLECULAR CANCER THERAPEUTICS
- Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress
- (2016) Tim I. M. Malcolm et al. Nature Communications
- Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) F. d'Amore et al. ANNALS OF ONCOLOGY
- Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases
- (2015) A. Fauconneau et al. BRITISH JOURNAL OF DERMATOLOGY
- Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma
- (2015) Ramona Crescenzo et al. CANCER CELL
- 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma
- (2015) John E. Janik et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
- (2015) T. A. Waldmann Cancer Immunology Research
- Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma
- (2014) Andre Weilemann et al. BLOOD
- ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
- (2014) E. R. Parrilla Castellar et al. BLOOD
- High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma
- (2014) Martin B Pedersen et al. HISTOPATHOLOGY
- Improved vectors and genome-wide libraries for CRISPR screening
- (2014) Neville E Sanjana et al. NATURE METHODS
- An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
- (2014) M. R. Mansour et al. SCIENCE
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
- (2013) Warren A. Whyte et al. CELL
- Super-Enhancers in the Control of Cell Identity and Disease
- (2013) Denes Hnisz et al. CELL
- TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
- (2013) Takaomi Sanda et al. Cancer Discovery
- Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas
- (2012) G. Vasmatzis et al. BLOOD
- Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma
- (2012) L. Agnelli et al. BLOOD
- PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas
- (2012) Daniela Laimer et al. NATURE MEDICINE
- miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma
- (2011) H. Matsuyama et al. BLOOD
- Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study
- (2011) Laurence Lamant et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-2R common -chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK
- (2011) Q. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: Establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity
- (2010) Melissa G. Lechner et al. CANCER
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
- (2010) Thomas R. Malek et al. IMMUNITY
- Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma
- (2010) H. Miles Prince et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma
- (2009) J. Iqbal et al. BLOOD
- NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells
- (2009) C. Ambrogio et al. CANCER RESEARCH
- Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma
- (2009) S. Mathas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas
- (2008) A L Feldman et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now